• 1
    Robinson R. Cost-benefit analysis. BMJ 1993; 307: 9246.
  • 2
    Adler MA, Posner EA, eds. Cost-Benefit Analysis: Legal, Economic and Philosophical Perspectives. Chicago: University of Chicago Press, 2001.
  • 3
    Goldfarb NM. Greg Koski on human subjects protection. J Clin Res Best Pract 2007; 3: 2. Available from, accessed 5 August 2010.
  • 4
    Humphreys K, Trafton J, Wagner TH. The cost of institutional review board procedures in multicenter observational research. Ann Intern Med 2003; 139: 77.
  • 5
    Vick CC, Finan KR, Kiefe C, Neumayer L, Hawn MT. Variation in institutional review processes for a multisite observational study. Am J Surg 2005; 190: 8059.
  • 6
    Stewart DF, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol 2010; 28: 292535 doi: 10.1200/JCO.2009.27.5404.
  • 7
    Nordhaus WD. The health of nations: the contribution of improved health to living standards. In: MurphyKM, TopelRH, eds. Measuring the Gains from Medical Research: An Economic Approach. Chicago: University of Chicago Press, 2003; 35.
  • 8
    Christie DRH, Gabriel GS, Dear K. Adverse effects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J 2007; 37: 6806.
  • 9
    See, for instance, Millar JA. Multicentre drug trials, ethics approval and death of patients. Intern Med J 2008; 38: 2989.
  • 10
    Collins R, Doll R, Peto R. Ethics of clinical trials. In: WilliamsCJ, ed. Introducing New Treatments for Cancer: Practical, Ethical, and Legal Problems. Chichester, UK: John Wiley & Sons Ltd, 1992; 4965.
  • 11
    CDC, DHHS, Hospital Care Statistics Branch, Division of Health Care Statistics. 1987 Summary: National Hospital Discharge Survey Number 159 (Rev), September 28, 1988.
  • 12
    Barron HV, Bowlby LJ, Breen T et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the national registry of myocardial infarction. Circulation 1998; 97: 11506.
  • 13
    Rogers EM. Diffusion of Innovations. 5th ed. New York: Free Press 2003; 272.
  • 14
    Drazen JM. Controlling research trials. N Engl J Med 2003; 348: 137780.
  • 15
    Kass NM, Pronovost PJ, Sugarman J, Goeschel CA, Lubomski LH, Faden R. Controversy and quality improvement: lingering questions about ethics, oversight, and patient safety research. Jt Comm J Qual Patient Saf 2008; 34: 34953.
  • 16
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 332: 34960; doi:10.1016/S0140-6736(88)92833-4.
  • 17
    Baigent C, Collins R, Appleby P et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 133743.